TNG:EPA
Transgene SA
€ 0.71
arrow_downward
-1.11%(-0.0080) Siku 1
1 Okt, 17:35:03 GMT +2 · EUR
search
Alama zote
| Alama | Bei | Tofauti | Tofauti ya asilimia |
|---|
insights_autoInatayarisha maarifa maarufu ya TNG...
Fungua
€ 0.72
Juu
€ 0.72
Chini
€ 0.71
Mtaji wa soko
200.83M
Wastani wa kiasi cha mauzo
elfu 158.58
Kiasi cha mauzo ya hisa
elfu 40.32
Juu kwa wiki 52
€ 1.50
Chini kwa wiki 52
€ 0.70
EPS
-€ 0.17
Hisa za wawekezaji
278.56M
Idadi ya wafanyakazi
160
Fungua
€ 0.72
Juu
€ 0.72
Chini
€ 0.71
Mtaji wa soko
200.83M
Wastani wa kiasi cha mauzo
elfu 158.58
Kiasi cha mauzo ya hisa
elfu 40.32
Juu kwa wiki 52
€ 1.50
Chini kwa wiki 52
€ 0.70
EPS
-€ 0.17
Hisa za wawekezaji
278.56M
Idadi ya wafanyakazi
160
Habari
Kutoka kwenye vyanzo vya wavuti na washirika wa habari
TipRanks
·
saa 6 zilizopita
Transgene to Showcase myvac® Cancer Vaccine Platform at Paris Investor Event
Wasifu
Transgene S.A. is a French biotechnology company founded in 1979. It is based in Illkirch-Graffenstaden, near Strasbourg, Alsace. The company develops and manufactures immunotherapies for the treatment of cancer. Based on viral vectors, these therapies stimulate the immune defenses of patients to specifically target cancer cells.
Transgene has two technological platforms based on these respective approaches: individual therapeutic vaccines, shared antigens cancer vaccines oncolytic viruses.
Transgene's portfolio consists of four products currently in clinical development. Its lead product TG4050, a neoantigen individualized therapeutic cancer vaccine is currently being developed in a randomized Phase I/II trial in the adjuvant treatment of head and neck cancer.
The company is listed on the regulated market of Euronext in Paris. Wikipedia
Kuhusu Transgene SA